This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sarepta Therapeutics, Inc.
Drug Names(s): AVI-5126
Description: Resten-CP is Resten-NG with AVI's proprietary CytoPorter (CP) attached to enhance delivery to the saphenous vein ex vivo before its use in bypass surgery.
Resten-NG is an antisense agent that targets the c-myc gene, which is believed to regulate the downstream genes that produce the pathology of restenosis: cell migration and adhesion, collagen formation, secretion of extra-cellular matrix, and cell proliferation, among others. The c-myc gene is immediately activated by the injury to the vascular lining during angioplasty and stent placement and peaks at 24 to 48 hours before subsiding. Resten-NG is a PPMO-based RNA (peptide–conjugated morpholino phosphorodiamidate oligomer), which uses morpholine rings instead of the standard nucleic acid rings in the backbones of RNA and DNA.
Resten-MP is a microparticle formulation of Resten-NG that can be delivered intravenously.
Additional information available to subscribers only: